Business
Scribe Therapeutics raises USD 128.7 million in IPO priced at top of range
Scribe Therapeutics Inc. (Nasdaq: SCTX), a clinical-stage biotechnology company co-founded by Nobel laureate Jennifer Doudna, priced an upsized initial...
Thyora Therapeutics launches with Moffitt covalent chemistry platform
Thyora Therapeutics, a Tampa, Florida-based biotechnology company, emerged from stealth with an exclusive worldwide license to covalent chemistry technology...
Synaptiq Therapeutics launches with acquisition of small-molecule rare disease therapy
Synaptiq Therapeutics, an Iceland-based clinical-stage biotechnology company, launched through the acquisition of SYN-001, a small molecule already in...
Transcripta secures USD 24m to advance AI-powered neurological drug platform
Palo Alto, California-based Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular diseases, has raised USD 24...
N-Zyme Bio secures USD 4.6m Series A to advance pepsin-targeted reflux therapies
Delaware-based N-Zyme Biomedical, a clinical-stage biotechnology company developing pepsin-targeted therapies for reflux disease, has closed a Series A...
Royalty Pharma bets USD 425m on AstraZeneca's amyloid-clearing antibody cliramitug
New York-based Royalty Pharma plc (Nasdaq: RPRX) has agreed to buy a slice of Neurimmune's royalty interest in cliramitug, AstraZeneca's Phase III antibody...
SKNV licenses Washington University immunotherapy patent for actinic keratosis
SKNV, a Fort Lauderdale, Florida-based compounding pharmacy and dermatology-focused drugmaker, has secured exclusive commercialization rights under a...
Dyne raises USD 375m ahead of first neuromuscular disease commercial launch
Waltham, Massachusetts-based Dyne Therapeutics, Inc. (Nasdaq: DYN) announced the pricing of an upsized public offering of common stock, raising...
Mentari adds USD 200m PIPE funding for PACAP-targeted migraine candidate
Waltham, Massachusetts-based Mentari Therapeutics, Inc. announced a $200 million private placement of common stock and pre-funded warrants, the second...
Jupiter Neuro expands into MDMA-derived psychiatry with USD 100m PharmAla deal
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) has signed a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual, exclusive US rights...
Tikva Allocell secures USD 8m to advance off-the-shelf CAR-T therapy for solid tumors
Singapore-based Tikva Allocell, a biotechnology company developing engineered, off-the-shelf allogeneic T-cell therapies for solid tumors, has closed an USD...
Crystalys raises USD 130m in Series B to advance dotinurad into Phase III gout trials
San Diego-based Crystalys Therapeutics, a clinical-stage biopharmaceutical company developing therapies for gout, has closed an oversubscribed USD 130...
Evogene pairs AI chemistry with ELEO to pursue oral PCSK9 inhibitors
Evogene Ltd. (Nasdaq: EVGN; TASE: EVGN) and ELEO Inc., a private South Korean biotech based in Daejeon, announced a collaboration to discover oral...
TYK Medicines secures USD 408 million from Qilu for China lung cancer drug rights
TYK Medicines, Inc. (HKEX: 2410), a Huzhou, China-based oncology drug developer, has struck a license and collaboration agreement with Qilu Pharmaceutical...
Roche's USD 700m deal for Nurix's BTK degrader clears antitrust review
Nurix Therapeutics (Nasdaq: NRIX) said its global collaboration with Roche to co-develop and co-commercialize bexobrutideg (NX-5948) has closed following...
The AllSci Brief
Systematic R&D and deal news. Daily.